Theravance Biopharma Inc expected to post a loss of 25 cents a share - Earnings Preview

Theravance Biopharma

10/05/2024 23:31

* Theravance Biopharma Inc  TBPH.OQ   TBPH.O  is expected
to show
a rise in quarterly revenue when it reports  results on May 13
for the period ending January 1 0001
    * The George Town Grand Cayman-based  company is expected to
report a 34.0% increase in revenue to $13.963 million from
$10.42 million a year ago, according to the mean estimate from 4
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Theravance Biopharma Inc
is
for a loss of 25 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Theravance
Biopharma Inc is $15.00​, above​ its last closing price
of $9.38. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.17       -0.15      -0.17     Missed  -14.3
  2023         -0.22                  -0.17             18.9
               -0.22       -0.21      -0.28     Missed  -42.1​
 Jan. 1 0001   -0.25       -0.25      -0.15     Beat    -42.1
 ​​Dec.        -0.17       -0.17      -0.15     Beat    13
 31 2022                                                
 Sep. 30 2022  -0.21       -0.18      -0.21     Missed  -15.1​
 Jan. 1 0001   0.09        0.11       -0.09     Missed  -182.6
 Jan. 1 0001   -0.11       -0.11      -0.22     Missed  -107.5
 This summary was machine generated May 10 at 22:30 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)